{
  "generated": "2025-11-06T07:07:41.835053+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/neurological/resveratrol-cogn-gen-0150/cognition/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "COGN-GEN-0150_01",
      "year": 2012,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "attention",
      "population": "Adults with attention concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/resveratrol-cogn-gen-0150-01",
      "url": "https://doi.org/10.1234/resveratrol-cogn-gen-0150-01",
      "citation": "COGN-GEN-0150_01 (2012); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with attention concerns; Outcome: attention; DOI: 10.1234/resveratrol-cogn-gen-0150-01; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "COGN-GEN-0150_02",
      "year": 2013,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "attention",
      "population": "Adults with attention concerns",
      "adverse_events": "Mild GI discomfort",
      "doi": "10.1234/resveratrol-cogn-gen-0150-02",
      "url": "https://doi.org/10.1234/resveratrol-cogn-gen-0150-02",
      "citation": "COGN-GEN-0150_02 (2013); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with attention concerns; Outcome: attention; DOI: 10.1234/resveratrol-cogn-gen-0150-02; Adverse Events: Mild GI discomfort."
    },
    {
      "study_id": "COGN-GEN-0150_03",
      "year": 2014,
      "design": "randomized controlled trial",
      "journal": "cognition_journal",
      "outcome": "attention",
      "population": "Adults with attention concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/resveratrol-cogn-gen-0150-03",
      "url": "https://doi.org/10.1234/resveratrol-cogn-gen-0150-03",
      "citation": "COGN-GEN-0150_03 (2014); Journal: cognition_journal; Design: randomized controlled trial; Population: Adults with attention concerns; Outcome: attention; DOI: 10.1234/resveratrol-cogn-gen-0150-03; Adverse Events: None reported."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-cogn-gen-0150-01",
      "study_ids": [
        "COGN-GEN-0150_01"
      ],
      "primary_study_id": "COGN-GEN-0150_01",
      "url": "https://doi.org/10.1234/resveratrol-cogn-gen-0150-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-cogn-gen-0150-02",
      "study_ids": [
        "COGN-GEN-0150_02"
      ],
      "primary_study_id": "COGN-GEN-0150_02",
      "url": "https://doi.org/10.1234/resveratrol-cogn-gen-0150-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/resveratrol-cogn-gen-0150-03",
      "study_ids": [
        "COGN-GEN-0150_03"
      ],
      "primary_study_id": "COGN-GEN-0150_03",
      "url": "https://doi.org/10.1234/resveratrol-cogn-gen-0150-03"
    }
  ],
  "manifest_hash": "sha256:2b36f3693ada799b9809102727d4534019e995509774d6da5514230bed3a2067"
}
